ID27986A - Pengobatan terhadap gangguan sistem syaraf pusat dengan modulator reseptor estrogen selektif - Google Patents

Pengobatan terhadap gangguan sistem syaraf pusat dengan modulator reseptor estrogen selektif

Info

Publication number
ID27986A
ID27986A IDW991190D ID991190D ID27986A ID 27986 A ID27986 A ID 27986A ID W991190 D IDW991190 D ID W991190D ID 991190 D ID991190 D ID 991190D ID 27986 A ID27986 A ID 27986A
Authority
ID
Indonesia
Prior art keywords
estrogent
selective
interference
treatment
receptor modulators
Prior art date
Application number
IDW991190D
Other languages
English (en)
Inventor
Kelly Renee Bales
Henry Uhlman Bryant
Steven Marc Paul
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID27986A publication Critical patent/ID27986A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW991190D 1997-04-09 1998-04-07 Pengobatan terhadap gangguan sistem syaraf pusat dengan modulator reseptor estrogen selektif ID27986A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4311797P 1997-04-09 1997-04-09

Publications (1)

Publication Number Publication Date
ID27986A true ID27986A (id) 2001-05-03

Family

ID=21925589

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991190D ID27986A (id) 1997-04-09 1998-04-07 Pengobatan terhadap gangguan sistem syaraf pusat dengan modulator reseptor estrogen selektif

Country Status (19)

Country Link
US (2) US6077852A (id)
EP (1) EP0986556A4 (id)
JP (1) JP2001518898A (id)
KR (1) KR20010006219A (id)
CN (1) CN1260792A (id)
AU (1) AU733421B2 (id)
BR (1) BR9809389A (id)
CA (1) CA2286455A1 (id)
EA (1) EA002360B1 (id)
HU (1) HUP0002031A3 (id)
ID (1) ID27986A (id)
IL (1) IL132278A0 (id)
NO (1) NO994901L (id)
NZ (2) NZ514146A (id)
PL (1) PL336701A1 (id)
TR (1) TR199902700T2 (id)
TW (1) TW479056B (id)
WO (1) WO1998045287A1 (id)
ZA (1) ZA982877B (id)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
EA200100039A1 (ru) 1998-06-16 2001-06-25 Эли Лилли Энд Компани Способы увеличения уровней ацетилхолина
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
TR200003714T2 (tr) * 1998-06-16 2001-07-23 Eli Lilly And Company Asetilkolin seviyesinin yükseltilmesi
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
RU2240318C2 (ru) * 1999-07-29 2004-11-20 Эли Лилли Энд Компани Новая кристаллическая форма 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил) бензо[b]тиофена гидрохлорида
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride
ES2208384T3 (es) * 1999-07-29 2004-06-16 Eli Lilly And Company Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno.
RU2240319C2 (ru) * 1999-07-29 2004-11-20 Эли Лилли Энд Компани Новая кристаллическая форма 6-гидрокси-3-(4-[2-(пиперидин-1-ил)этокси]фенокси)-2-(4-метоксифенил) бензо[b]тиофена гидрохлорида
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
CA2691739A1 (en) * 2000-05-08 2001-11-15 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo [b]thiophene and salts thereof
CZ20031098A3 (cs) * 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
US8124776B2 (en) * 2007-03-16 2012-02-28 Eli Lilly And Company Process and intermediates for preparing arzoxifene
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
NZ710385A (en) 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN104829569B (zh) * 2015-05-12 2017-04-26 广州中医药大学 一种2‑苯基‑苯骈五元杂环类化合物及其衍生物的应用
CN104829568B (zh) * 2015-05-12 2017-03-01 广州中医药大学 一种2‑苯基‑苯骈五元杂环类化合物及其衍生物的医药应用
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
JP2021534177A (ja) * 2018-08-16 2021-12-09 ジー１ セラピューティクス， インコーポレイテッド 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
AU2021342287A1 (en) 2020-09-14 2023-04-13 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
DE1300575B (de) * 1965-05-21 1969-08-07 Bristol Myers Co Benzo[b]thiophene
US3394125A (en) * 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4117128A (en) * 1976-08-03 1978-09-26 Smithkline Corporation Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8705174D0 (en) * 1987-03-05 1987-04-08 Ici Plc Heterocyclic compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5439931A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5512296A (en) * 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
NZ514146A (en) 2001-09-28
NO994901L (no) 1999-12-09
HUP0002031A3 (en) 2003-01-28
AU733421B2 (en) 2001-05-17
EP0986556A4 (en) 2001-03-21
NO994901D0 (no) 1999-10-08
JP2001518898A (ja) 2001-10-16
ZA982877B (en) 1999-10-04
EA002360B1 (ru) 2002-04-25
KR20010006219A (ko) 2001-01-26
NZ500175A (en) 2001-10-26
TW479056B (en) 2002-03-11
WO1998045287A1 (en) 1998-10-15
BR9809389A (pt) 2002-03-19
HUP0002031A2 (hu) 2001-06-28
CN1260792A (zh) 2000-07-19
CA2286455A1 (en) 1998-10-15
US6077852A (en) 2000-06-20
AU7104998A (en) 1998-10-30
US20020013342A1 (en) 2002-01-31
TR199902700T2 (xx) 2000-06-21
IL132278A0 (en) 2001-03-19
PL336701A1 (en) 2000-07-03
EA199900913A1 (ru) 2000-04-24
EP0986556A1 (en) 2000-03-22

Similar Documents

Publication Publication Date Title
ZA982877B (en) Treatment of central nervous system disorders with selective estrogen receptor modulators.
ID23183A (id) Perangsangan modulator reseptor asam amino
EG25606A (en) Glucocorticoid receptor modulators
EP1140086A4 (en) N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
AU2482100A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69822337D1 (de) Mischkatalysatorsystem
IL133822A0 (en) Aroylpiperazines for modulating sexual activity
ZA991301B (en) Glutamate receptor modulators.
EP0971588A4 (en) NEW CANNABINOID RECEPTOR MODULATORS
ID27816A (id) Sistem dan metode untuk penyesuaian unit-unit komunikasi tanpa kabel
AU2056700A (en) 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
DE69638263D1 (de) Pulsmodulationsverfahren, pulsmodulator und pulsdemodulator
DE69840285D1 (de) Mehrkanaliger akustisch-optischer Modulator
GB2321808B (en) Single sideband modulators
AU7592998A (en) Modulators of tissue regeneration
DE69818142D1 (de) TDMA Kommunikationssystem
DE69827759D1 (de) Kommunikationssystem, kommunikationssteuerverfahren und kommunikationssteuerung
GB9702099D0 (en) Secure communication system
GB9710402D0 (en) Light modulating devices
DE69832560D1 (de) FM-Modulator
DE69631151D1 (de) Mehrträgermodulation
DE69619629D1 (de) Katalytischer Einsatz zur NOx-Reduzierung
AU2783099A (en) Receptor derived peptides as modulators of receptor activity
NO975851D0 (no) Cytoplasmatiske modulatorer av integrinregulering/-signalisering